Our study particularly highlighted an essential role of JNK MAPK isoform in the modulation of barrier function by plasma obtained from CD patients and provides new evidence for potential applications of JNK inhibition in IBD therapy. The gene discussed is MAPK8; the disease is inflammatory bowel disease.